FDA approves prostate cancer imaging agent
Choline C 11 Injection, a PET scan imaging agent, is now available for men with elevated PSA levels after earlier treatment for prostate cancer.
Diagnosis & Disease Information
Cancer survivors uneasy with primary care follow-up
Lack of cancer expertise, continuity of care cited as barriers to receiving follow-up cancer care from primary care providers.
FDA approves new test for prostate cancer
The Prostate Health Index is a non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than prostate-specific antigen in patients with PSA values in the 4-10 ng/mL range.
When to Screen for Prostate Cancer
Screening for prostate cancer has long been part of the yearly checkup for many men. Although this procedure may reduce a patient’s risk for dying from the disease, evidence is conflicting about how helpful it actually is in reducing mortality. Because many prostate cancers are slow growing, treatment often does more psychological and physical harm…
USPSTF recommends against PSA-based screening
Based on the evidence, the U.S. Preventive Services Task Force gave a grade D recommendation against PSA-based screening for men in the general U.S. population, regardless of age.
Prostate cancer: To screen or not to screen?
Only 50% of clinicians surveyed agree with U.S. Preventive Services Task Force recommendations not to perform routine PSA screening.
Uncertainty common when deciding to stop PSA screening
Many clinicians find it difficult to determine when it’s appropriate to stop screening patients for prostate cancer.
Jury still out on value of PSA screening
Extended follow-up data from the European Randomized Study of Screening for Prostate Cancer shows screening reduced risk of death from prostate cancer, but not all-cause mortality.
Vitamin E may hurt prostate and saw palmetto doesn’t help
Two studies offer data about the effects if vitamin E and saw palmetto on the prostate.
Androgen-deprivation plus radiation may improve prostate cancer survival
Research suggests that androgen-deprivation therapy improves survival when added to radiotherapy in men with locally advanced, stage T3 or T4 prostate cancer or with prostate cancer with high metastatic risk.
- Loading...
Loading...
Loading... 
Loading...